GeneDx: Why I Think The Worst Is Behind The Business

GeneDx shows early signs of operational recovery, with Q2 revenue and margins exceeding expectations and testing volumes up 32%. Reimbursement rates have stabilized, and management expects meaningful improvements in Q4 and a stronger recovery in 2027. Valuation remains attractive, with a Buy rating maintained. Upside potential exists if reimbursement and growth targets are met. Risks include delayed reimbursement recovery, slower payer coverage, and ongoing cash burn, though liquidity has been recently strengthened.

GeneDx ( WGS ) reported Q2 results that suggest Q1 may have been the operational bottom of the slowdown, with testing volumes still growing strongly, reimbursement rates.